home / stock / eras / eras news

ERAS News and Press, Erasca Inc. From 08/11/23

Stock Information
Company Name: Erasca Inc.
Stock Symbol: ERAS
Market: NASDAQ
Website: erasca.com
Menu
ERAS ERAS Quote ERAS Short ERAS News ERAS Articles ERAS Message Board
Get ERAS Alerts

News, Short Squeeze, Breakout and More Instantly...
ERAS - Eton, Semler top healthcare gainers; Cano, Kezar among losers

2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...
ERAS - Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple meaningful clinical catalysts over the next 18 months and beyond Strong balance s...

ERAS - Erasca: Trading Near Cash Value

2023-07-12 02:46:43 ET Summary Shares of precision oncology concern Erasca have tumbled 80% from their IPO pricing in June 2021 as early-stage clinical data from its programs have failed to impress. To get it closer to commercialization, ERAS in-licensed pan-RAF inhibitor naporafe...

ERAS - MTTR, CMPS and HBIO are among after hour movers

2023-06-26 17:20:36 ET Gainers: Terns Pharmaceuticals ( NASDAQ: TERN ) +7% . Savara ( SVRA ) +5% . Nkarta ( NKTX ) +5% . COMPASS Pathways  ( CMPS ) +3% . Matterport ( MTTR ) +2% . Losers: Adicet  ( ACET ...
ERAS - FDA grants orphan drug status to Erasca brain cancer drug ERAS-801

2023-06-22 17:53:09 ET The US Food and Drug Administration has granted orphan drug status to Erasca's ( NASDAQ: ERAS ) drug candidate ERAS-801 for the treatment of malignant brain tumors, including glioblastoma. Erasca said the designation could entitle ERAS-801 to seven years o...

ERAS - Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology co...

ERAS - GH, GREE and TAST are among after hour movers

2023-06-14 17:14:52 ET Gainers: TrueCar ( TRUE ) +9% . RF Industries ( RFIL ) +8% . Carrols Restaurant ( TAST ) +5% . Inventiva ( IVA ) +5% . Erasca ( ERAS ) +5% . Losers: Gambling ( GAMB ) -12% . SEALSQ ( L...
ERAS - Kinnate Biopharma: Trading Below Cash Value

2023-06-11 09:51:51 ET Summary Shares of precision oncology concern Kinnate Biopharma Inc. (KNTE) have crashed 93% from their all-time high as long overdue data from a Phase 1 study failed to impress. The company is advancing a couple of early-stage compounds but has hit some bump...

ERAS - Sientra, ContraFect top healthcare gainers; Elevation, Longboard among losers

2023-06-09 10:07:38 ET Gainers: Sientra ( SIEN ) +65% . ContraFect ( CFRX ) +47% . Societal CDMO ( SCTL ) +20% . Akili ( AKLI ) +14% . Erasca ( ERAS ) +12% . Losers: Elevation Oncology ( ELEV ) -41% . Longboar...

ERAS - Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK inhibitor Ongoing clinical programs for naporafenib, ERAS-007, ERAS-601, and ERAS-801 in ...
Previous 10 Next 10